Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael D Altman

Showing results (11-20 of 45) with videos related to

Pageof 5
Sort By:
ACS Medicinal Chemistry Letters|December 21, 2016
Carboxamide Spleen Tyrosine Kinase (Syk) Inhibitors: Leveraging Ground State Interactions To Accelerate OptimizationJ Michael Ellis, Michael D Altman, Brandon Cash, et al.
Molecular Pharmaceutics|March 23, 2017
Analyzing the Potential Root Causes of Variability of Pharmacokinetics in Preclinical SpeciesPierre Daublain, Kung-I Feng, Michael D Altman, et al.
Journal of Medicinal Chemistry|February 6, 2009
Additivity in the analysis and design of HIV protease inhibitorsRobert N Jorissen, G S Kiran Kumar Reddy, Akbar Ali, et al.
Chemistry & Biology|September 10, 2013
Substrate envelope-designed potent HIV-1 protease inhibitors to avoid drug resistanceMadhavi N L Nalam, Akbar Ali, G S Kiran Kumar Reddy, et al.
Journal of Virology|March 19, 2010
Evaluating the substrate-envelope hypothesis: structural analysis of novel HIV-1 protease inhibitors designed to be robust against drug resistanceMadhavi N L Nalam, Akbar Ali, Michael D Altman, et al.
Bioorganic & Medicinal Chemistry Letters|March 4, 2014
The discovery of reverse tricyclic pyridone JAK2 inhibitors. Part 2: lead optimizationTony Siu, Sathyajith E Kumarasinghe, Michael D Altman, et al.
ACS Medicinal Chemistry Letters|September 18, 2020
Allosteric Modulation of Protein Arginine Methyltransferase 5 (PRMT5)Rachel L Palte, Sebastian E Schneider, Michael D Altman, et al.
Bioorganic & Medicinal Chemistry Letters|November 4, 2010
The discovery of tricyclic pyridone JAK2 inhibitors. Part 1: hit to leadTony Siu, Ekaterina S Kozina, Joon Jung, et al.
Bioorganic & Medicinal Chemistry Letters|March 27, 2014
Thiophene carboxamide inhibitors of JAK2 as potential treatments for myleoproliferative neoplasmsAndrew M Haidle, Anna A Zabierek, Kaleen K Childers, et al.
Chemical Biology & Drug Design|June 2, 2007
Design of mutation-resistant HIV protease inhibitors with the substrate envelope hypothesisSripriya Chellappan, G S Kiran Kumar Reddy, Akbar Ali, et al.
Pageof 5

Showing results (11-20 of 45) with videos related to

Sort By:
Pageof 5
ACS Medicinal Chemistry Letters|December 21, 2016
Carboxamide Spleen Tyrosine Kinase (Syk) Inhibitors: Leveraging Ground State Interactions To Accelerate OptimizationJ Michael Ellis, Michael D Altman, Brandon Cash, et al.
Molecular Pharmaceutics|March 23, 2017
Analyzing the Potential Root Causes of Variability of Pharmacokinetics in Preclinical SpeciesPierre Daublain, Kung-I Feng, Michael D Altman, et al.
Journal of Medicinal Chemistry|February 6, 2009
Additivity in the analysis and design of HIV protease inhibitorsRobert N Jorissen, G S Kiran Kumar Reddy, Akbar Ali, et al.
Chemistry & Biology|September 10, 2013
Substrate envelope-designed potent HIV-1 protease inhibitors to avoid drug resistanceMadhavi N L Nalam, Akbar Ali, G S Kiran Kumar Reddy, et al.
Journal of Virology|March 19, 2010
Evaluating the substrate-envelope hypothesis: structural analysis of novel HIV-1 protease inhibitors designed to be robust against drug resistanceMadhavi N L Nalam, Akbar Ali, Michael D Altman, et al.
Bioorganic & Medicinal Chemistry Letters|March 4, 2014
The discovery of reverse tricyclic pyridone JAK2 inhibitors. Part 2: lead optimizationTony Siu, Sathyajith E Kumarasinghe, Michael D Altman, et al.
ACS Medicinal Chemistry Letters|September 18, 2020
Allosteric Modulation of Protein Arginine Methyltransferase 5 (PRMT5)Rachel L Palte, Sebastian E Schneider, Michael D Altman, et al.
Bioorganic & Medicinal Chemistry Letters|November 4, 2010
The discovery of tricyclic pyridone JAK2 inhibitors. Part 1: hit to leadTony Siu, Ekaterina S Kozina, Joon Jung, et al.
Bioorganic & Medicinal Chemistry Letters|March 27, 2014
Thiophene carboxamide inhibitors of JAK2 as potential treatments for myleoproliferative neoplasmsAndrew M Haidle, Anna A Zabierek, Kaleen K Childers, et al.
Chemical Biology & Drug Design|June 2, 2007
Design of mutation-resistant HIV protease inhibitors with the substrate envelope hypothesisSripriya Chellappan, G S Kiran Kumar Reddy, Akbar Ali, et al.
Pageof 5